Commencement of the Phase 1 Clinical Trial of VectorFlu™ ONE
- hkubio2021
- Mar 1, 2020
- 1 min read
Phase 1 clinical trials of VectorFlu™ ONE, the world's first COVID-19 nasal vaccine, developed by the research team of HKU Department of Microbiology, commenced in March 2021 at the HKU Phase 1 Clinical Trials Centre.



